Read the story here. Advertise at Before It's News here.
Profile image
Story Views
Last hour:
Last 24 hours:

Colorectal Cancer Therapeutics 2020 Market Forecast, Deals and Strategic Consolidations

% of readers think this story is Fact. Add your two cents.

ReportsnReports adds Colorectal Cancer Therapeutics market research to its database. The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020.

The report provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.

Get a sample copy of this research at .

The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies. Stivarga is expected to be one of the biggest drivers of growth in the CRC market, primarily due to its expected line extension in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in 2014, in the thirdand fourth-line settings will further increase the pharmacological treatment rates in these lines, which will give patients a more tolerable alternative to Stivarga. The moderate uptake of other late-stage pipeline products, panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market.

The CRC pipeline is highly robust, with potential drug candidates across various Phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

Complete research of 104 pages with TOC is available at .


The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. It includes -

  • A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to -

  • Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

List of Tables

Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013 15
Table 2 Surgical Options for Colorectal Cancer 16
Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014 68
Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014 70
Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2014 75
Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014 75
Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014 80
Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014 86
Table 9: Colorectal Cancer Therapeutics, Global, Forecast Data, 2013-2020 87
Table 10: Colorectal Cancer Therapeutics, US, Forecast Data, 2013-2020 87
Table 11: Colorectal Cancer Therapeutics, Canada, Forecast Data, 2013-2020 88
Table 12: Colorectal Cancer Therapeutics, UK, Forecast Data, 2013-2020 88
Table 13: Colorectal Cancer Therapeutics, France, Forecast Data, 2013-2020 88
Table 14: Colorectal Cancer Therapeutics, Germany, Forecast Data, 2013-2020 89
Table 15: Colorectal Cancer Therapeutics, Italy, Forecast Data, 2013-2020 89
Table 16: Colorectal Cancer Therapeutics, Spain, Forecast Data, 2013-2020 89
Table 17: Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013-2020 90
Table 18: Colorectal Cancer Market, References for Heat Map 99

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.